Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)Recruiting
NCT06780098Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm
United States, Chile, China, Germany, Greece +6 more
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).Recruiting
NCT06655324Phase 1Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Nirogacestat in Ovarian Granulosa Cell TumorsCompleted
NCT05348356Phase 2Updated Aug 25, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Ovarian Granulosa-Stromal Tumor · Ovarian Granulosa Cell Tumor · Ovarian Cancer
United States, Canada, Poland
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseNot Yet Recruiting
NCT07750158Phase 3Updated Aug 25, 2026
Sponsor: Exelixis
Colorectal Cancer
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel ResectionCompleted
NCT06112353Phase 4Updated Aug 25, 2026
Sponsor: University of California, Irvine
Intestinal Disease
United States
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)Not Yet Recruiting
NCT07785609Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Tumors · Malignant Neoplasm
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)Active Not Recruiting
NCT06956235Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Hidradenitis Suppurativa
United States, Argentina, Australia, Canada, Chile +10 more
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting
NCT04165798N/AUpdated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Recruiting
NCT06780085Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Chile, Germany, Greece, Hungary +5 more
A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)Not Yet Recruiting
NCT07785830Phase 1Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)Completed
NCT07532304Phase 1Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)Recruiting
NCT04165070Phase 1, Phase 2Updated Aug 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more
Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruiting
NCT06997276Phase 1Updated Aug 24, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Healthy · Hepatic Impairment
United States
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Recruiting
NCT06136650Phase 3Updated Aug 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer (mCRPC) · Prostatic Neoplasms
United States, Australia, Brazil, Canada, Chile +34 more
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior ChemotherapyNot Yet Recruiting
NCT07639086Phase 2Updated Aug 24, 2026
Sponsor: Virginia Commonwealth University
Prostate Cancer · Neuroendocrine Prostate Cancer (NEPC)
United States
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaActive Not Recruiting
NCT02858921Phase 2Updated Aug 24, 2026
Sponsor: Melanoma Institute Australia
Melanoma
Australia
Surgical Pembro +/- Olaparib w TMZ for rGBMActive Not Recruiting
NCT05463848Phase 2Updated Aug 24, 2026
Sponsor: L. Nicolas Gonzalez Castro, MD, PhD
Glioblastoma · Recurrent Glioblastoma
United States
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Recruiting
NCT07044297Phase 3Updated Aug 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
United States, Argentina, Brazil, Chile, Colombia +11 more
A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)Not Yet Recruiting
NCT07595263Phase 1Updated Aug 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe FibrosisCompleted
NCT02973503Phase 3Updated Aug 24, 2026
Sponsor: University Hospital, Clermont-Ferrand
Chronic HCV Infection
France
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaCompleted
NCT02991482Phase 3Updated Aug 24, 2026
Sponsor: ETOP IBCSG Partners Foundation
Pleural Mesothelioma Malignant Advanced
Spain, Switzerland, United Kingdom
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)Recruiting
NCT06863272Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Castration-Resistant Prostatic Cancer · Metastasis
United States, Argentina, Australia, Brazil, Canada +14 more
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).Terminated
NCT04949256Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Esophageal Squamous Cell Carcinoma
United States, Argentina, Canada, Chile, China +20 more
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Active Not Recruiting
NCT05458297Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Follicular Lymphoma · Richter Transformation Lymphoma
United States, Brazil, Canada, Chile, China +16 more
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)Completed
NCT03940703Phase 2Updated Aug 21, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer
United States, Belgium, China, France, Germany +12 more

Previous page Next page